

## **Transgene's novel drug against Breast Cancer provides encouraging results**

February 22, 2010

Transgene Biotek is happy to report that a new drug for treating Breast Cancer, developed using Transgene's proprietary RNAi technology platform, has demonstrated exciting results in its latest animal studies. This drug is specifically designed not only to treat primary Breast Cancer but also to fight against potential metastatic tumours.

The new Breast Cancer drug follows on the heels of a Liver Cancer drug that showed similarly encouraging data in earlier animal studies, and was also developed using Transgene's RNAi platform. The platform employs a novel gene silencing technology which involves the highly selective knock-down of specific Breast Cancer producing gene targets, and has demonstrated remarkable regression of tumours in animal studies. Transgene's ability to generate its own novel mutant vectors for highly efficient drug delivery, which is vital in the treatment of such cancers, is important to this technology.

Worldwide, breast cancer is the most common cancer in women, representing 16% of all female cancers, and causes well over 500,000 deaths annually.

Various types of cancer, including Breast Cancer, can spread beyond the original organ to other parts of the body, and these are known as metastatic tumours, which TBL's drug helps to fight.

The success of the Breast Cancer drug in animal trials further validates the inherent soundness and strength of the novel technology platforms that Transgene has been developing carefully during the last 4-5 years.